Oppenheimer Asset Management’s Xenon Pharmaceuticals XENE Stock Holding History

Oppenheimer Asset Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$255K	Sell	4,217 -108	-2%	-$6K	﹤0.01%	1031
2026 Q1	$251K	Buy	+4,325	New	+$199K	﹤0.01%	1006
2024 Q4	–	Sell	-5,306	Closed	-$209K	–	1201
2024 Q3	$209K	Sell	5,306 -74	-1%	-$2.98K	﹤0.01%	1091
2024 Q2	$210K	Buy	5,380 +6	+0.1%	+$240	﹤0.01%	1071
2024 Q1	$231K	Buy	5,374 +946	+21%	+$43.5K	﹤0.01%	1017
2023 Q4	$204K	Sell	4,428 -1,783	-29%	-$63K	﹤0.01%	1083
2023 Q3	$212K	Sell	6,211 -19	-0.3%	-$711	﹤0.01%	1041
2023 Q2	$240K	Buy	+6,230	New	+$248K	﹤0.01%	1022

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Oppenheimer Asset Management's XENE Position: Q2 2026 in Review

Oppenheimer Asset Management reduced its Xenon Pharmaceuticals (XENE) stake by 2.5% in Q2 2026, selling an estimated $6K and leaving 4,217 shares worth $255K. The position accounts for ﹤0.01% of the portfolio, ranked #1031.

Oppenheimer Asset Management first reported a position in XENE in Q2 2023 and has held it in 8 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Oppenheimer Asset Management held 4,217 shares of Xenon Pharmaceuticals worth $255K as of Q2 2026.
Oppenheimer Asset Management sold 108 Xenon Pharmaceuticals shares in Q2 2026, an estimated $6K.
Xenon Pharmaceuticals made up ﹤0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #1031 holding.
Oppenheimer Asset Management first reported a position in Xenon Pharmaceuticals in Q2 2023 and has held it in 8 quarters since.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.